Record Details

Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial

Hematology Reports

View Archive Info
 
 
Field Value
 
Authentication Code dc
 
Title Statement Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial
 
Added Entry - Uncontrolled Name Hans E. Johnsen; Department of Haematology, Aalborg Hospital, Aarhus University Hospital
Lene M. Knudsen; Department of Haeatology, Odense University Hospital
Anne K. Mylin; Rigshospitalet
Peter Gimsing; Department of Haematology, Rigshospitalet
Henrik Gregersen; Department of Haematology, Aalborg Hospital, Aarhus University Hospital
Niels Abildgaard; Department of Haematology, Odense University Hospital
Niels Frost Andersen; Department of Haematology, Aarhus Hospital, University of Aarhus
Torben Plesner; Department of Haematology, Vejle Hospital
Annette Vangsted; Department of Haematology, Herlev Hospital, University of Copenhagen
Torben Mourits-Andersen; Department of Haematology, Esbjerg Hospital
The Nordic Myeloma Study Group; Schering Nordic AB; Amgen AB; Nordic Cancer Union; the Danish Cancer Society; the Danish Research Agency; the EU 6th FP
 
Uncontrolled Index Term Medicine; Hematology; Multiple Myeloma
Multiple Myeloma; Clinical trial; Fludarabine
 
Summary, etc. The impact of chemotherapy resistant B cells in multiple myeloma (MM) needs to be evaluated by in vivo targeted therapy. Here we report the conclusions from a phase II randomized, placebo controlled trial adding fludarabine to the induction with cyclophosphamide-dexamethasone. Based on an interim toxicity and safety analysis, the trial was stopped following inclusion of 34 of a planned 80 patients due to a reduced number of patients (4/17) actually harvested in the experimental arm compared to the control arm (11/17; p lower than 0.05). In conclusion, the scheduled fludarabine dosage in 2 cycles combined with alkylating therapy impairs stem cell mobilization and standard therapy in young MM patients and should not be administrated up-front.
 
Publication, Distribution, Etc. PAGEPress Publications
2009-07-01
 
Electronic Location and Access application/pdf
text/html
http://www.pagepress.org/journals/index.php/hr/article/view/hr.2009.e11
 
Data Source Entry Hematology Reports; Vol 1, No 2 (2009); e11
 
Language Note en
 
Terms Governing Use and Reproduction Note <p>PAGEPress has chosen to apply the <a href="http://creativecommons.org/licenses/by-nc/3.0/" target="_blank">Creative Commons Attribution License</a> (CCAL) to all manuscripts to be published. </p> <p>An Open Access Publication is one that meets the following two conditions:</p> <ol><li>The author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.</li><li>A complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.</li></ol> Authors who publish with this journal agree to the following terms: 1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. 2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. 3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).